ABSTRACT
OBJECTIVES: To investigate the effectiveness and safety of homeopathic medicine Natrum muriaticum (LM2) for mild cases of COVID-19 in Primary Health Care. TRIAL DESIGN: A randomized, two-armed (1:1), parallel, placebo-controlled, double-blind, clinical trial is being performed to test the following hypotheses: H0: homeopathic medicines = placebo (null hypothesis) vs. H1: homeopathic medicines ≠ placebo (alternative hypothesis) for mild cases of COVID-19 in Primary Care. PARTICIPANTS: Setting: Primary Care of São Carlos - São Paulo - Brazil. One hundred participants aged 18 years or older, with Influenza-like symptoms and a positive RT-PCR for SARS-CoV-2. Willingness to give informed consent and to comply with the study procedures is also required. Exclusion criterium: severe acute respiratory syndrome. INTERVENTION AND COMPARATOR: Homeopathy: 1 globule of Natrum muriaticum LM2 diluted in 20 mL of alcohol 30% and dispensed in a 30 ml bottle. Placebo: 20 mL of alcohol 30% dispensed in a 30 ml bottle. Posology: one drop taken orally every 4 hours (6 doses/day) while there is fever, cough, tiredness, or pain (headache, sore throat, muscle aches, chest pain, etc.) followed by one drop every 6 hours (4 doses/day) until the fourteenth day of use. The bottle of study medication should be submitted to 10 vigorous shakes (succussions) before each dose. Posology may be changed by telemedicine, with no break in blinding. Study medication should be maintained during home isolation. According to the Primary Care protocol, the home isolation period lasts until the 10th day after the appearance of the first symptom, or up to 72 hours without symptoms. MAIN OUTCOMES: The primary endpoint will be time to recovery, defined as the number of days elapsed before all COVID-19 Influenza-like symptoms are recorded as mild or absent during home isolation period. Secondary measures are recovery time for each COVID-19 symptom; score of the scale created for the study (COVID-Simile Scale); medicines used during follow-up; number of days of follow-up; number of visits to emergency services; number of hospitalizations; other symptoms and Adverse Events during home isolation period. RANDOMISATION: The study Statistician generated a block randomization list, using a 1:1 ratio of the two groups (denoted as A and B) and a web-based tool ( http://www.random.org/lists ). BLINDING (MASKING): The clinical investigators, the statistician, the Primary Care teams, the study collaborators, and the participants will remain blinded from the identity of the two treatment groups until the end of the study. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): One hundred participants are planned to be randomized (1:1) to placebo (50) or homeopathy (50). TRIAL STATUS: Protocol version/date May 21, 2020. Recruitment is ongoing. First participant was recruited/included on June 29,2020. Due to recruitment adaptations to Primary Care changes, the authors anticipate the trial will finish recruiting on April 10, 2021. TRIAL REGISTRATION: COVID-Simile Study was registered at the University Hospital Medical Information Network (UMIN - https://www.umin.ac.jp/ctr/index.htm ) on June 1st, 2020, and the trial start date was June 15, 2020. Unique ID: UMIN000040602. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
Subject(s)
COVID-19/therapy , Homeopathy/methods , Materia Medica/administration & dosage , Primary Health Care/methods , SARS-CoV-2/genetics , Sodium Chloride, Dietary/administration & dosage , Administration, Oral , Adolescent , Adult , Aged , Aged, 80 and over , Brazil/epidemiology , COVID-19/epidemiology , COVID-19/virology , Double-Blind Method , Female , Follow-Up Studies , Homeopathy/adverse effects , Humans , Male , Middle Aged , Randomized Controlled Trials as Topic , Reverse Transcriptase Polymerase Chain Reaction , Treatment Outcome , Young AdultABSTRACT
OBJECTIVES: Male gender and high-salt diet are risk factors for hypertension. The effect of chronic exposure to testosterone is an increase in vascular tone but its influence upon responses induced by other vasoactive agents is not clear. We considered the possibility of interactions between testosterone and a high-salt diet in the mechanisms that are involved in the regulation of vascular tone. Therefore, we designed experiments to assess the involvement of the cyclic adenosine monophosphate (cAMP) pathway and potassium channel activation on vascular relaxation elicited by testosterone deficiency that was induced by orchidectomy in Sprague Dawley rats on a normal or high-salt diet. METHOD: Weanling male rats were randomly divided into eight groups (n = 6 each) that were either orchidectomized or sham operated with or without testosterone replacement (10 mg/kg body weight of Sustanon 250 intramuscularly, Organon, Holland) and were placed on a normal or high-salt (0.3% or 8% NaCl) diet, respectively, for 6 weeks. Arterial blood pressure was determined before and weekly throughout the experiment using the tail-cuff method. Relaxation responses to forskolin and diazoxide were studied in noradrenaline (0.1 µM) precontracted aortic rings. RESULTS: There was an increase in the systolic blood pressure of rats placed on a high-salt diet compared with control or orchidectomized rats. Orchidectomy elicited a reduction in the systolic blood pressure while testosterone replacement restored systolic blood pressure to values seen in intact rats. A high-salt diet reduced the relaxation response to forskolin and diazoxide but not in orchidectomized rats while testosterone replacement re-established the blunted relaxation response to forskolin and diazoxide. CONCLUSION: Inhibition of potassium channel or adenylyl cyclase activation appears to contribute to the mechanisms by which a high-salt diet increases vascular tone. These effects were counteracted by orchidectomy in male Sprague Dawley rats.
Subject(s)
Aorta/metabolism , Aorta/physiopathology , Cyclic AMP/metabolism , Hypertension/etiology , KATP Channels/metabolism , Orchiectomy , Sodium Chloride, Dietary , Testosterone/metabolism , Vasodilation , Adenylyl Cyclases/metabolism , Animals , Aorta/drug effects , Arterial Pressure , Disease Models, Animal , Enzyme Activation , Enzyme Activators/pharmacology , Hormone Replacement Therapy , Hypertension/metabolism , Hypertension/physiopathology , KATP Channels/drug effects , Male , Rats , Rats, Sprague-Dawley , Second Messenger Systems , Testosterone/administration & dosage , Testosterone/deficiency , Time Factors , Vasodilation/drug effects , Vasodilator Agents/pharmacologyABSTRACT
The objective of this study was to evaluate the performance and parasitologic infection of male dairy cattle submitted to supplemental proteic salt with and without the use of homeopathic medicines. Were used crossbred Gir x Holstein castrated males calves, with 10 months of age and live weight of 150.75 kg, distributed in a completely randomized design with eight replicates per treatment, totaling 16 animals. The calves of each treatment remained in a pasture of Brachiaria brizantha cv. Marandu, managed in continuous grazing system for 8 months. The treatments employed were: supplementation with 300 g/animal/day of protein (40% of crude protein (CP) and 25% CP in the dry and rainy season, respectively) added or not with 5 g/animal/day of the homeopathic medicines FATOR PRO® and C & MC®. The addition of homeopathic medicines in the protein supplement did not affect (P > 0.05) the development of body male crossbred to pasture. The counting of the larvae and adults of ticks in scrapings were lower (P < 0.05) in animals that did not receive homeopathic medicines in the protein supplement. The females tick in the body anterior third (simplifying counting), nymphs in scrapings and the number of eggs per gram of helminths were not affected (P > 0.05) by the treatments. It was concluded that the use of homeopathic medicines did not affect the development of male crossbred Gir x Holstein dairy cattle neither their parasitic infection.